Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios

Transfusion

Volumn 53, Issue 10, 2013, Pages 2399-2412

  Bruhn, Roberta ^a,b,c   Lelie, Nico ^a,b,c   Custer, Brian ^a,b,c   Busch, Michael ^a,b,c   Kleinman, Steven ^a,b,c   Vermeulen, Marion ^d   Reddy, Ravi ^d   Bird, Arthur ^e   Cable, Russell ^e   Goubran, Heidi ^f   Moftah, Faten ^f   El Ekiaby, Magdy ^g   Ghiazza, Paola ^h   Manzini, Paola ⁱ   Favilli, Flavia ^j   Peduzzi, Cecilia ^k   Roig, Roberto ^l   Alvarez, Manolo ^l   Sauleda, Silvia ^m   Niederhauser, Christoph ⁿ   Levicnik, Snezna ^o   Nograsek, Polona ^o   Wessberg, Sussanne ^p   Elkblom, Sussane ^p   Lankinen, Mervi ^p   Ulm, Henrik ^q   Harritshoj, Lene ^q   Nielsen, Christian ^r   Jorgensen, Steffen ^s   Erikstrup, Christian ^t   O’Riordan, Joan ^u   Brojer, Ewa ^v   Grabarczyk, Piotr ^v   Gdowska, Jolanta ^w   Piotrowski, Dariusz ^w   Lam, Sally ^x   Teo, Diane ^x   Chua, Sze Sze ^x   Lin, Che Kit ^y   Tsoi, Wai Chiu ^y   Bon, Abdul Hamid ^z   Peng, Sally Lam Tsuey ^z   Flanagan, Peter ^aa   Brown, Stewart ^ab   Kiely, Philip ^ab   Margaritis, Angelo ^ab   more..

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b Lelie Research   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SOUTH AFRICAN NATIONAL BLOOD SERVICE   (South Africa)

^e Western Province Blood Transfusion Service   (South Africa)

^f National Blood Transfusion Center   (Egypt)

^g Shabrawishi Hospital   (Egypt)

^h S ANNA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF PISA   (Italy)

^k CAREGGI UNIVERSITY HOSPITAL   (Italy)

^l Valencia Transfusion Center   (Spain)

^m BANC DE SANG I TEIXITS   (Spain)

ⁿ Blood Transfusion Service SRC Berne   (Switzerland)

^o BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^p FINNISH RED CROSS BLOOD SERVICE   (Finland)

^q Mental Health Services CPH   (Denmark)

^r ODENSE UNIVERSITY HOSPITAL   (Denmark)

^s Transfusion Center   (Denmark)

^t AARHUS UNIVERSITY HOSPITAL   (Denmark)

^u IRISH BLOOD TRANSFUSION SERVICE   (Ireland)

^v INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^w Regional Centre of Blood Transfusion   (Poland)

^x HEALTH SCIENCES AUTHORITY   (Singapore)

^y Hong Kong Red Cross Blood Transfusion Service   (Hong Kong)

^z National Blood Center   (Malaysia)

^aa New Zealand Blood Service   (New Zealand)

^ab AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA; VIRUS ANTIBODY;

ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION; MAJOR CLINICAL STUDY; RISK ASSESSMENT; SCREENING; SOUTH AFRICA; VIRION; VIRUS LOAD; ASIA; BLOOD; COMPARATIVE STUDY; EUROPE; GENETICS; GEOGRAPHY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MASS SCREENING; PACIFIC ISLANDS; PROCEDURES; SEROLOGY; STANDARDS; STATISTICS AND NUMERICAL DATA; TIME; TRANSMISSION; DISEASE TRANSMISSION; METHODOLOGY; STANDARD; STATISTICS;

ANTIBODIES, VIRAL; ASIA; BLOOD DONORS; BLOOD TRANSFUSION; EUROPE; GEOGRAPHY; HIV INFECTIONS; HIV SEROPREVALENCE; HIV-1; HUMANS; MASS SCREENING; OCEANIA; RNA, VIRAL; SEROLOGIC TESTS; SOUTH AFRICA; TIME FACTORS;

EID: 84891723845     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12299     Document Type: Article

References (25)

1. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Reesink HW et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102: 82-90.
2. Weusten J, Vermeulen M, van Drimmelen H, Lelie N. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-15.
3. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25.
4. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27:406-16.
5. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002;42:537-48.
6. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9.
7. Ma ZM, Stone M, Piatak M Jr., Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009;83:3288-97.
8. Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Fickett T, Busch M, Lelie N. Comparison of HIV assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion. 2013. DOI: 10.1111/trf.12117.
9. Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis 1996;174:26-33.
10. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
11. Vermeulen M, Coleman C, Gaggia L, Sykes W, Crookes R, Lelie N, Gulube S, Busch M, Reddy R. The effect of change in testing strategy and increasing the black donor base on the HIV window period transmission risk in South Africa: a five year analysis. 3D-S12-01. Vox Sang 2011;101 Suppl 1:41.
12. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504.
13. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-64.
14. Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nubling CM. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012;52:431-9.
15. Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, Polonis VR, Rao M, Alving CR. Human erythrocytes selectively bind and enrich infectious HIV-1 virions. Plos ONE 2009;4:e8297.
16. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83:329-35.
17. Hess C, Klimkait T, Schlapbach L, Del Zenero V, Sadallah S, Horakova E, Balestra G, Werder V, Schaefer C, Battegay M, Schifferli JA. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002;359: 2230-4.
18. Kupfer B, Matz B, Daumer MP, Roden F, Rockstroh JK, Qurishi N, Spengler U, Kaiser R. Frequent detection of cellassociated HIV-1 RNA in patients with plasma viral load <50 copies/ml. J Med Virol 2007;79:1440-5.
19. Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O’Connell RJ, O’Doherty U, Chun TW, Migueles SA et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 2012;119:4645-55.
20. Apetrei C, Loussert-Ajaka I, Descamps D, Damond F, Saragosti S, Brun-Vezinet F, Simon F. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 1996;10:F57-F60.
21. Niederhauser C, Strohle A, Stolz M, Muller F, Tinguely C. The risk of a second diagnostic window with 4th generation HIV assays: two cases. J Clin Virol 2009;45: 367-9.
22. Speers D, Phillips P, Dyer J. Combination assay detecting both human immunodeficiency virus (HIV) p24 antigen and anti-HIV antibodies opens a second diagnostic window. J Clin Microbiol 2005;43:5397-9.
23. Meier T, Knoll E, Henkes M, Enders G, Braun R. Evidence for a diagnostic window in fourth generation assays for HIV. J Clin Virol 2001;23:113-16.
24. Mukadi BK, Vandercam B, Bodeus M, Moreau M, Goubau P. An HIV seroconversion case: unequal performance of combined antigen/antibodies assays. AIDS 2002;16: 127-8.
25. Goodrich R, Custer B, Keil S, Busch M. Defining “adequate” pathogen reduction performance for transfused blood components. Transfusion 2010;50:1827-37.